methyl 7-cyano-8-(3,6-dihydro-2H-pyran-4-yl)naphthalene-2-carboxylate | 1239129-36-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并呋喃类
• 英文名称: methyl 7-cyano-8-(3,6-dihydro-2H-pyran-4-yl)naphthalene-2-carboxylate
• CAS: 1239129-36-2
• 化学式: C₁₈H₁₅NO₃
• 分子量: 293.322
• InChiKey: QXOTWIKSQRGQKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  59.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED)
  申请人：Kinoyama Isao

  公开号：US20120041036A1

  公开（公告）日：2012-02-16

  An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on serotonin 5-HT 5A receptor modulating action. It was discovered that acylguanidine derivatives, in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent the 5-HT 5A receptor modulating action and excellent pharmacological actions based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.

  本发明的目的是提供一种基于血清素5-HT5A受体调节作用的用于治疗或预防痴呆症、精神分裂症的优良药剂。发现酰基胍衍生物，其中胍基通过一个羰基与萘的一个环相结合，另一个环上结合有一个环状基团，表现出强效的5-HT5A受体调节作用和基于该作用的优良药理作用。本发明可用作治疗或预防痴呆症、精神分裂症、躁郁症或注意力缺陷多动障碍的优良药剂。
• SUBSTITUTED ACYLGUANIDINE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP2394988A1

  公开（公告）日：2011-12-14

  An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on serotonin 5-HT5A receptor modulating action. It was discovered that acylguanidine derivatives, in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent the 5-HT5A receptor modulating action and excellent pharmacological actions based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.

  本发明的目的是提供一种基于5-羟色胺5-HT5A受体调节作用的治疗或预防痴呆症、精神分裂症的优良药物。 研究发现，酰基胍衍生物（其中胍通过羰基键合在萘的一个环上，环基键合在其另一个环上）具有强效的 5-HT5A 受体调节作用和基于该作用的优异药理作用。本发明可作为治疗或预防痴呆症、精神分裂症、双相情感障碍或注意缺陷多动障碍的优良药物。